CEO Crowley: Amicus will go it alone on migalastat Phase III success
This article was originally published in Scrip
Executive Summary
Amicus Therapeutics proved to investors on 20 August that the confidence it held in its lead Fabry disease drug candidate was valid, announcing positive results from its second Phase III trial of migalastat. Now a long regulatory road is ahead of the small New Jersey biotech firm, but CEO John Crowley says to "stay tuned."
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.